Scarlett Shen China

Fosunpharma is a leading healthcare group in China. It has built a strong root domestically and developed a global operation strategy. With pharmaceutical manufacturing and R&D being core business segment, together with strong presences in medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Looking for investment opportunities
Headquartner in China
Fosun Pharma
Investment manager 
Functionality

Nan Shen China

Keytone is a venture firm with AUM over $400m.
Partnering Objectives
Headquartner in China
Keytone Ventures
Shen 

Hongjian红健 Shen沈 China

leadermed Group是一家将美国正在临床阶段创新药license in China以及亚洲部分国家的公司,致力于将国外最新研究成果以最快速度让China乃至亚洲其他国家患者使用上国际最安全有效创新药,将来也将自主研发我们China人自己的创新药,为世界上所有患者服务!
Partnering Objectives
Headquartner in China
leadermed Group
共同创始合伙人 

Mrs. Ari Silverman China

MAVIE Technologies is an investment banking boutique in Chinese-Western healthcare transactions providing commercially-focused, end to end advice to maximize deal certainty and increase the intended value of transactions. Our team combines deal structuring sophistication and experience - whether it is private placement, secondary shares sale, joint-venture, licensing or M&A - with deep Chinese healthcare insights, strategic thinking and proprietary access. We add unique value in visualizing, negotiating and closing the deal.
Mavie Technologies
Partner 

Di Simon China

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).
Website:
Chinawanbang.com
Partnering Objectives
Headquartner in China
Wanbang Biopharmaceuticals (Group) Co., Ltd
高级BD经理 

ZIWEI SONG China

Well renown venture capital firm in China.
Website:
www.szvc.com.cn
Partnering Objectives
Headquartner in China
Shenzhen Capital Group Co. , Ltd.
投资 

Jizhe Sun China

Founded in 1999, BGI is one of the world's leading life science and genomics organizations.
Website:
www.genomics.cn
Partnering Objectives
Headquartner in China
BGI Group
Supervisor of the Board of Director’s Office 

Xiaolu Sun China

Healthcare VC
Partnering Objectives
Headquartner in China
Proxima Ventures
Founder 

Meng Sun China

华润集团一级利润中心,聚焦生命科学领域投资与合作
Partnering Objectives
Headquartner in China
华润生命科学集团
Senior manager, investment 

Dr. Jun Sun China

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological&Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has more than 8000 employees, 70% of which have the college degree or above.

Qilu pharmaceutical has always been sticking to the innovative development strategy. Guided by the market demand and the product innovation, Qilu has established extensive cooperation with domestic and foreign partners on a series of R&D projects. Qilu pays high attention to the introduction and cultivation of talents and has built a highly qualified R&D team with professional and efficient R&D capabilities, More than 100 national new drugs have been successfully developed, which constitutes the reasonable production line for the future development of Qilu. A number of technological achievements have obtained the national and provincial scientific & technological progress awards and created good social benefit.

Qilu Pharmaceutical has eight manufacturing sites covering an area of more than 2800,000 ㎡for finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The modern workshops are located in the manufacturing sites where the automatic production lines, key equipments and analytical instruments are imported from the leading suppliers all over the world. Now Qilu Pharmaceutical has been one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Qilu pharmaceutical has always been committing itself to providing the high-quality products to the patients and the society. Thanks to the integrated and stringent system of quality control and quality assurance, the company has been the leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.
Qilu Pharmaceutical North America
VP, Business Development 
Functionality